Mode of selection and experimental evolution of antiviral drugs resistance in vesicular stomatitis virus

Infection, Genetics and Evolution

Volumn 5, Issue 1, 2005, Pages 55-65

  Cuevas, José M ^a   Sanjuán, Rafael ^a   Moya, Andrés ^a   Elena, Santiago F ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Ciudad Politécnica de la Innovación   (Spain)

Author keywords

Interferon; Cost of resistance; Experimental evolution; Ribavirin; RNA viruses

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENOTYPE; GROWTH RATE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; EVOLUTION, MOLECULAR; GENOTYPE; INTERFERON-ALPHA; MUTATION; RIBAVIRIN; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 10244221176     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2004.06.006     Document Type: Article

References (61)

1. A. Airaksinen N. Pariente L. Menéndez-Arias E. Domingo Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis Virology 311 2003 339-349
2. M.A. Bracho A. Moya E. Barrio Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity J. Gen. Virol. 79 1998 2921-2928
3. J.H. Braconier O. Paulsen K. Engman A. Widell Combined alpha- interferon and ribavirin treatment in chronic hepatitis C: A pilot-study Scand. J. Infect. Dis. 27 1995 325-329
4. Y.K. Chow M.S. Hirsch D.P. Merrill L.J. Bechtel J.J. Eron J.C. Kaplan R.T. D'Aquila Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy Nature 361 1993 650-654
5. S. Crotty D. Maag J.J. Arnold W.D. Zhong J.Y.N. Lau Z. Hong R. Andino C.E. Cameron The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Nature Med. 6 2000 1375-1379
6. S. Crotty C.E. Cameron R. Andino RNA virus error catastrophe: Direct molecular test by using ribavirin Proc. Natl. Acad. Sci. U.S.A. 98 2001 6895-6900
7. J.M. Cuevas S.F. Elena A. Moya Molecular basis of adaptive convergent in experimental populations of RNA viruses Genetics 162 2002 533-542
8. E.A. Duarte D.K. Clarke A. Moya E. Domingo J.J. Holland Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet Proc. Natl. Acad. Sci. U.S.A. 89 1992 6015-6019
9. A. Dulioust S. Paulous L. Guillemot A.M. Delavalle F. Boue F. Clavel Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors J. Virol. 73 1999 850-854
10. M. Eigen Self-organization of matter and evolution of biological macromolecules Naturwissenschaften 58 1971 465-523
11. M.W. Fried J.H. Hoofnagle Therapy of hepatitis C Sem. Liver. Dis. 15 1995 82-91
12. S.D. Frost A.R. McLean Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection AIDS 8 1994 323-332
13. U. Fuchizaki S. Kaneko Y. Nakamoto Y. Sugiyama K. Imagawa M. Kikuchi K. Kobayashi Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus J. Med. Virol. 69 2003 188-194
14. Q. Gao Z. Gu H. Salomon K. Nagai M.A. Parniak M.A. Wainberg Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1 Arch. Virol. 136 1994 111-122
15. Q. Gao M.A. Parniak Z. Gu M.A. Wainberg Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or ddI but no by combinations Leukemia 6 1992 192S-195S
16. P.J. Gerrish J.G. García-Lerma Mutation rate and the efficacy of antimicrobial drug treatment Lancet Infect. Dis. 3 2003 28-32
17. J. Goudsmit A. de Ronde D.D. Ho A.S. Perelson Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase J. Virol. 70 1996 5662-5664
18. J.D. Graci C.E. Cameron Quasispecies, error catastrophe, and the antiviral activity of ribavirin Virology 298 2002 175-180
19. A. Grande-Pérez S. Sierra M.G. Castro E. Domingo P.R. Lowenstein Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity Proc. Natl. Acad. Sci. U.S.A. 99 2002 12938-12943
20. D.D. Ho A.U. Neumann A.S. Perelson W. Chen J.M. Leonard M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123-126
21. J.J. Holland E. Domingo J.C. de la Torre D.A. Steinhauer Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis J. Virol. 64 1990 3960-3962
22. J.H. Hoofnagle Management of hepatitis C: Current and future perspectives J. Hepatol. 31 1999 264-268
23. M.D. Iglesias-Ussel C. Casado E. Yuste I. Olivares C. López-Galíndez In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants J. Gen. Virol. 83 2002 93-101
24. T. Imamichi S.C. Berg H. Imamichi J.C. López J.A. Metcalf J. Falloon H.C. Lane Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr → Gly) at codon 69 J. Virol. 74 2000 10958-10964
25. J. Izopet C. Souyris A. Hance K. Sanders-Sauné M. Alvarez C. Pasquier F. Clavel J. Puel P. Massip Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype J. Infect. Dis. 185 2002 1506-1510
26. G.H. Kijak V. Simon P. Balfe J. Vanderhoeven S.E. Pampuro C. Zala C. Ochoa P. Cahn M. Markowitz H. Salomon Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure J. Virol. 76 2002 7000-7009
27. M.B. Klein N. Campeol R.G. Lalonde B. Brenner M.A. Wainberg Didanosine, interferon-alfa and ribavirin: A highly synergistic combination with potential activity against HIV-1 and hepatitis C virus 17 2003 1001-1008
28. E. Kojima T. Shirasaka B.D. Anderson S. Chokekijchai S.M. Steinberg S. Broder R. Yarchoan H. Mitsuya Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy J. Infect. Dis. 171 1995 1152-1158
29. P. Kontsek E. Kontsekova Forty years of interferon Acta Virol. 41 1997 349-353
30. M.J. Kozal N. Shah N. Shen R. Yang R. Fucini T.C. Merigan D.D. Richman D. Morris E. Hubbell M. Chee T.R. Gingeras Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays Nat. Med. 2 1996 753-759
31. B.A. Larder S.D. Kemp P.R. Harrigan Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy Science 269 1995 696-699
32. C.H. Lee D.L. Gilbertson I.S. Novella R. Huerta E. Domingo J.J. Holland Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus J. Virol. 71 1997 3636-3640
33. L.A. Loeb J.M. Essigmann F. Kazazi J. Zhang K.D. Rose J.I. Mullins Lethal mutagenesis of HIV with mutagenic nucleoside analogs Proc. Natl. Acad. Sci. U.S.A. 96 1999 1492-1497
34. L.M. Mansky D.K. Pearl L.C. Gajary Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies J. Virol. 76 2002 9253-9259
35. R. Miralles P.J. Gerrish A. Moya S.F. Elena Clonal interference and the evolution of RNA viruses Science 285 1999 1745-1747
36. I. Nájera A. Holguin M.E. Quiñones-Mateu M.A. Muñoz-Fernández R. Nájera C. López-Galíndez E. Domingo Pol gene quasispecies of human immunodeficiency virus mutations associated with drug resistance in virus from patients undergoing no drug therapy J. Virol. 69 1995 23-31
37. I. Nájera D.D. Richman I. Olivares J.M. Rojas M.A. Peinado M. Perucho R. Nájera C. López-Gálindez Natural occurrence of drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates AIDS Res. Hum. Retrovir. 10 1994 1479-1488
38. D. Neau T. Galperine E. Legrand V. Pitard M. Neau-Cransac J.F. Moreau J.M. Ragnaud M. Dupon H. Fleury M.E. Lafon T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin HIV Med. 4 2003 120-126
39. I.S. Novella M. Cilnis S.F. Elena J. Kohn A. Moya E. Domingo J.J. Holland Large-population passages of vesicular stomatitis virus in interferon-treated cells select variants of only limited resistance J. Virol. 70 1996 6414-6417
40. M.A. Nowak S. Bonhoeffer C. Loveday P. Balfe M. Semple S. Kaye M. Tenant-Flowers R. Tedder HIV results in the frame. Results confirmed Nature 375 1995 193
41. N. Pariente S. Sierra P.R. Lowenstein E. Domingo Efficient virus extinction by combinations of a mutagen and antiviral inhibitors J. Virol. 75 2001 9723-9730
42. J.K. Pfeiffer K. Kirkegaard A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity Proc. Natl. Acad. Sci. U.S.A. 100 2003 7289-7294
43. F. Querenghi Q. Yu G. Billaud G. Maertens C. Trepo F. Zoulim Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy J. Viral. Hepat. 8 2001 120-131
44. R.M. Ribeiro S. Bonhoeffer Production of resistant HIV mutants during antiretroviral therapy Proc. Natl. Acad. Sci. U.S.A. 97 2000 7681-7686
45. R.M. Ribeiro S. Bonhoeffer M.A. Nowak The frequency of resistant mutant virus before antiviral therapy AIDS 12 1998 461-465
46. D.D. Richman Antiviral drug resistance: Issues and challenges. In: D.D. Richman (Ed.) Antiviral Drug Resistance 1996 John Wiley & Sons San Diego 1-9
47. D.D. Richman The implications of drug resistance for strategies of combination antiviral chemotherapy Antivir. Res. 29 1996 31-33
48. D.D. Richman D. Havlir J. Corbeil D. Looney C. Ignacio S.A. Spector J. Sullivan S. Cheeseman K. Barringer D. Pauletti Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy J. Virol. 68 1994 1660-1666
49. S.W. Schalm B.E. Hansen L. Chemello A. Bellobuono J.T. Brouwer O. Weiland L. Cavalletto R. Schvarcz G. Ideo A. Alberti Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers J. Hepatol. 26 1997 961-966
50. R. Schuurman M. Nijhuis R. van Leeuwen P. Schipper D. de Jong P. Collis S.A. Danner J. Mulder C. Loveday C. Christopherson Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) J. Infect. Dis. 171 1995 1411-1419
51. G.C. Sen Viruses and interferons Annu. Rev. Microbiol. 55 2001 255-281
52. W.E. Severson C.S. Schmaljohn A. Javadian C.B. Jonsson Ribavirin causes error catastrophe during hantaan virus replication J. Virol. 77 2003 481-488
53. S. Sierra M. Dávila P.R. Lowenstein E. Domingo Response of foot-and-mouth disease virus to increased mutagénesis: Influence of viral load and fitness in loss of infectivity J. Virol. 74 2000 8316-8323
54. J. Sreenarasimhaiah A. Jaramillo J. Crippin M. Lisker-Melman W.C. Chapman T. Mohanakumar Concomitant augmentation of type 1 CD4(+) and CD8(+) T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection Hum. Immunol. 64 2003 497-504
55. R.R. Sokal F.J. Rohlf Biometry 1995 W.H. Freeman and Co. New York
56. R.C. Tam J.Y. Lau Z. Hong Mechanisms of action of ribavirin in antiviral therapies Antivir. Chem. Chemother. 12 2001 261-272
57. A. Tsubota Y. Hirose N. Izumi H. Kumada Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection British J. Clin. Pharmacol. 55 2003 360-367
58. S.B. Vandepol L. Lefrancois J.J. Holland Sequences of the major antibody binding epitopes of the Indiana serotype of vesicular stomatitis virus Virology 148 1986 312-325
59. K.C. Young K.L. Lindsay K.J. Lee W.C. Liu J.W. He S.L. Milstein M.M. Lai Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy Hepatology 38 2003 869-878
60. X. Wei S.K. Ghosh M.E. Taylor V.A. Johnson E.A. Emini P. Deutsch J.D. Lifson S. Bonhoeffer M.A. Nowak B.H. Hahn Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117-122
61. P.A. Whitaker-Dowling D.K. Wilcox C.C. Widnell J.S. Youngner Interferon-mediated inhibition of virus penetration Proc. Natl. Acad. Sci. U.S.A. 80 1983 1083-1086